UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 24, 2015
LION BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in Charter)
| NEVADA | ||
| (State of Incorporation) | ||
| 000-53127 | 75-3254381 | |
| (Commission File Number) | (I.R.S. Employer Identification No.) | |
| 21900 Burbank Boulevard | ||
| Third Floor | ||
| Woodland Hills, California | 91367 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| (818) 992-3126 | ||
| (Registrant’s Telephone Number, Including Area Code) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
| Item 2.02 | Results of Operation and Financial Condition |
Lion Biotechnologies (“we,” “us,” “our” or the “company”) is currently in the process of finalizing its financial results for the fiscal year ended December 31, 2014. While complete financial information is not available, based on information currently available, we estimate that as of December 31, 2014, we had approximately $44.9 million of cash and cash equivalents. These preliminary estimates have been prepared by, and are the responsibility of, our management. Our actual cash and cash equivalents as of December 31, 2014 may differ from these estimates due to the completion of our closing procedures with respect to the fiscal year ended December 31, 2014, final adjustments and other developments that may arise between now and the time the financial results are finalized.
| Item 8.01 | Other Events |
On February 24, 2015, we received approval from Nasdaq to list our common stock on the Nasdaq Global Market. Trading of our common stock on Nasdaq is expected to start on February 26, 2015 under the company's prior stock symbol "LBIO". Prior to the listing of our common stock on Nasdaq, our common stock was quoted on the OTCQB Marketplace.
This Current Report on Form 8-K contains forward-looking statements, including statement regarding expected financial results as of December 31, 2014 and the commencement of trading on Nasdaq. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. The company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from the Company’s historical experience and its present expectations or projections. These risks and uncertainties include, but are not limited to, risks related to changes in estimated financial amounts based on the completion of financial closing procedures and the audit of the financial statements and market risks and uncertainties, as well as those described in “Item 1A. Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K and those described from time to time in other reports which the Company files with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: February 25, 2015 |
LION BIOTECHNOLOGIES, INC.
| ||
| By: | /s/MICHAEL HANDELMAN | ||
| Michael Handelman, Chief Financial Officer | |||